Stock RVMD REVOLUTION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Real-time Estimate Cboe BZX
Other stock markets
 02:08:47 2024-04-29 pm EDT 		5-day change 1st Jan Change
36.76 USD +2.21% Intraday chart for Revolution Medicines, Inc. +0.99% +28.28%
Apr. 12 Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating MT
Apr. 12 Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
AQ
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs
AQ
Revolution Medicines to Participate in Upcoming Investor Conferences
AQ
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
AQ
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
AQ
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
AQ
Revolution Medicines to Participate in Upcoming Investor Conferences
AQ
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
AQ
Revolution Medicines Completes Acquisition of EQRx
AQ
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
AQ
Revolution Medicines : RVMD Corporate Presentation
PU
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
AQ
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
AQ
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
AQ
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
AQ
Revolution Medicines : First-in-Human Phase 1/1b Trial of the First-in-Class Bi-Steric mTORC1 Selective Inhibitor RMC-5552 in Patients with Advanced Solid Tumors
PU
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
AQ
Revolution Medicines : Preliminary Safety and Pharmacokinetic Profiles of RMC-6236, a First-in-class, RAS-selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Solid Tumors on the Phase 1 Trial RMC-6236-001
PU
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVMD Stock
  4. News Revolution Medicines, Inc.
  5. Press Releases